Tan et al. reported (April 2024) a patient with EGFR-mutant, BRAF V600E NSCLC who developed acquired MAP2K1 K57N after EGFR/BRAF/MEK therapy; the combination with furmonertinib showed clinical activity before resistance emerged. This evidence concerns the gene EGFR and non-small cell lung carcinoma.